Tag: GlobeNewswire

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS 

Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis

EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced two abstracts selected for presentation at the MSToronto2026 10^th Joint ACTRIMS-ECTRIMS Meeting, taking place from October 21-23, 2026, in Toronto, Canada.

“We are excited to share these data, which demonstrate the sustained clinical benefit achieved following a single dose of miv-cel in our registrational SPS trial, alongside encouraging findings from the updated Phase 1 IIT study in progressive multiple sclerosis,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. “Together, these data, combined with a well-tolerated safety profile, reinforce our confidence in miv-cel’s differentiated profile and potential to redefine the treatment paradigm for neurologic autoimmune diseases. As we advance toward completing our BLA in our initial indication this quarter, we are also laying the groundwork for the commercial launch of miv-cel, which, if approved, could become the first CAR T-cell therapy for autoimmune disease and the first approved treatment for SPS.”

Poster Presentation:
Title: 1-Year Analysis of KYSA-8: the Pivotal, Multicenter, Phase 2 Study of Miv-cel (Mivocabtagene Autoleucel; Formerly KYV-101) CD19 CAR T-Cell Therapy in Stiff Person Syndrome
Presenter: Dr. Amanda Piquet, M.D., FAAN, Director of Autoimmune Neurology at the University of Colorado Anschutz School of Medicine
Poster ID: P0364
Date & Time: Wed., Oct. 21, 2026, 4:30 – 6:30 PM ET

Oral Presentation:
Title: Safety and Preliminary Efficacy of CD-19 Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: A Phase 1 Study
Presenter: Dr. Jeff Dunn, M.D., Lily Sarafan Director of Neuroimmunology and Clinical Professor & Chief of Neuroimmunology in the Department of Neurology & Neurological Sciences at Stanford University
Date & Time: Friday, Oct. 23,2026, 11:05 – 11:15 AM ET

About Stiff Person Syndrome (SPS)
SPS is a rare, progressive neurologic autoimmune disease characterized by muscle stiffness and painful muscle spasms, impacting mobility and gait. Stiffness, rigidity, and spasms in the torso, arms, and legs lead to progressive disability causing up to 80% of patients to lose mobility, requiring walking aid assistance or wheelchair use^1-3. SPS has been shown to lead to permanent disability and increased risk of mortality³. Most patients with SPS have antibodies to glutamic acid decarboxylase 65 (GAD65) or the glycine receptor, which disrupt normal inhibitory neurotransmission, contributing to the hallmark symptoms of SPS. There are currently no FDA-approved treatments for SPS. Current treatment options include symptomatic treatments, off-label immunotherapies, such as intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, as well as supportive care and physical, speech, occupational, and psychiatric therapy; however, the majority of patients have inadequate or no response to these treatment options. An estimated 6,000 patients are diagnosed with SPS in the United States^4-5.

About Multiple Sclerosis
Multiple sclerosis is a chronic autoimmune disease causing neurodegeneration, in which patients can experience a range of symptoms including blurred vision, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, and, in severe cases, the inability to walk or stand. B cells play a significant role in MS by producing autoantibodies that attack the protective sheath around nerves, activating T cells, and increasing inflammation. Current disease-modifying treatments for MS aim to reduce the frequency of disease relapses and delay progression of disability, but the disease remains a chronic condition that will progressively worsen for most patients.

About Miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further reinforcing the therapy’s potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for a single dose of miv-cel to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases; the potential for miv-cel to redefine the treatment paradigm for neurologic autoimmune diseases and to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; the possibility of a commercial launch of the first CAR T-cell therapy to potentially be approved for autoimmune disease and the first approved treatment for SPS; the anticipated timing of the completion of the rolling BLA submission for miv-cel in SPS; Kyverna’s pipeline opportunities, including in progressive multiple sclerosis; and Kyverna’s potentially first-in-class neuroimmunology franchise. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; risks related to the timing and outcome of regulatory submissions and interactions with the FDA; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that topline results may change following further analysis or differ from final results; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; and other factors discussed in the “Risk Factors” section of Kyverna’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com

¹ Rakocevic G, et al. BMC Neurol. 2019;19:1.
² Dalakas MC. Nat Rev Neurol. 2024;20(10):587-601.
³ Duddy ME, Baker MR. Front Neurol Neurosci. 2009;26:147-165.
⁴ Crane PD, et al. Neurology. 2024;103(12):e210078.
⁵ Analysis of 2024 Komodo U.S. Claims Data.

Series C structure establishes conversion timing and quarterly limits as Company works toward engagement of MBP Global LLP

SOUTHLAKE, Texas, Oct. 07, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTCQB: AMFN) (“American Fusion” or the “Company”), developer of the proprietary Texatron™ Fusion Engine™, today announced agreements to restructure existing stock-based compensation rights with an aggregate maximum contractual amount of $2.88 million into Series C Convertible Preferred Stock. The exchange is part of the Company’s broader capital restructuring effort in support of its planned national securities exchange listing and institutional financing initiatives.

Preferred Equity Exchange

The agreements cover twelve officers, directors, consultants and advisors, each with an existing contractual compensation basis of $240,000. They provide for issuance of up to 288,000 Series C preferred shares in total, subject to the applicable earning and exchange provisions. The exchange involves no cash payment by either party.

The Series C structure establishes defined conversion eligibility and quarterly limits for shares issued in connection with these compensation arrangements. The $2.88 million represents the maximum contractual compensation covered by the agreements, rather than a stated reduction in recorded liabilities. The amounts recognized in the Company’s financial statements and the resulting balance-sheet effect remain subject to accounting review.

“This restructuring brings greater clarity to our compensation commitments and establishes a defined schedule for conversion into common stock,” said Brent Nelson, Executive Chairman of American Fusion. “We appreciate the support of our team and advisors as we organize our capital structure and advance our financing and planned uplisting initiatives.”

Conversion Timing and Capital Structure

Conversions may begin in the first full calendar quarter following the later of full vesting under the underlying compensation agreement and the earlier of the twentieth trading day after a national securities exchange listing or nine months after the original issue date. Once eligible, holders may convert up to 30% of their original entitlement in each of the first three quarters, with the remaining balance eligible in the fourth quarter. Unused quarterly allowances do not carry forward. These provisions regulate conversion timing and are not a blanket prohibition on transfers.

Each Series C share is initially convertible into one common share, subject to adjustments under the Certificate of Designation. Conversion is also subject to a beneficial ownership limitation initially set at 4.99%, which a holder may increase to no more than 9.99% on at least 61 days’ notice. The certificate separately limits voting on an as-converted basis to 4.99%.

The preferred shares’ $10 face value is a contractual term, not a forecast or guarantee of the common stock’s trading price. Future restructuring events are subject to the adjustment provisions in the governing documents; other changes require the applicable approvals and amendments. Holders have no right to require redemption. The Company has a limited option to repurchase the preferred shares at 125% of face value before the earlier of a national exchange listing or nine months after the original issue date.

The exchange agreements specify September 30, 2026 as their effective date.

Auditor Transition

JV CPA Inc., a boutique Houston-based firm, resigned as American Fusion’s independent registered public accounting firm effective October 1, 2026, citing health reasons. The Company’s Item 4.01 disclosure states that there were no disagreements with JV CPA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, and no reportable events, during the periods covered. JV CPA’s letter to the SEC confirms its agreement with those statements.

The Company is in the process of engaging MBP Global LLP, a PCAOB-registered firm with over 40 years of operating history and extensive experience serving public companies, as its successor auditor. MBP Global would audit the Company’s consolidated financial statements for the year ending December 31, 2026 and review its interim financial statements for the quarter ended September 30, 2026. MBP Global’s client acceptance and onboarding procedures are underway. The engagement remains subject to completion of those procedures, and MBP Global has not yet formally accepted the engagement.

“We’re prioritizing the information and coordination MBP Global needs to complete its acceptance process and begin the interim review,” said Brent Nelson, Executive Chairman. “As our operations grow more complex, strong and timely financial reporting is central to preparing for institutional financing and a planned exchange listing.”

Additional details are available in the Company’s Current Report on Form 8-K filed October 6, 2026, and its exhibits.

About American Fusion Inc.

American Fusion Inc. (OTCQB: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing the Texatron™ Fusion Engine™ aneutronic fusion platform, designed for modular, infrastructure-grade deployment across industrial, commercial, defense and grid-constrained applications.

The Company’s development strategy emphasizes system-level engineering, disciplined intellectual-property protection and scalable architectures intended to support long-term commercial operation, while maintaining a focus on capital discipline and transparent corporate governance.

For more information about American Fusion and its Texatron™ platform, please visit: americanfusionenergy.com

View the American Fusion Investor Deck here.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s capital restructuring, anticipated preferred-share issuances and conversions, accounting treatment, planned national securities exchange listing, institutional financing, prospective engagement of MBP Global LLP and timing of financial reporting, as well as the development and commercialization of the Texatron™ Fusion Engine™. Words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should” and “will” identify forward-looking statements.

These statements reflect current expectations and assumptions and are subject to risks and uncertainties, including completion of auditor acceptance procedures, accounting determinations, required approvals, exchange listing requirements, financing availability, market conditions, and scientific, engineering, regulatory and commercialization risks described in the Company’s SEC filings. Actual results may differ materially. Texatron™ remains under development and has not demonstrated fusion ignition, net energy gain or commercial electrical generation. There can be no assurance that the Company will complete its planned financing, uplisting or auditor engagement on anticipated terms or timing, or achieve its development objectives. Readers should not place undue reliance on forward-looking statements. American Fusion undertakes no obligation to update them except as required by law.

Corporate Communications

833-872-2636 ext. 730
ir@americanfusionenergy.com
info@americanfusionenergy.com
americanfusionenergy.com

Expanded Portfolio Addresses Demand for Secure, High-Throughput Communications Across Swarm-Scale Unmanned Operations

Palo Alto, California, Oct. 07, 2026 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB) (“Mobilicom” or the “Company”), a provider of cybersecure solutions for drones and robotics today announced its participation in the Association of the United States Army’s (AUSA) 2026 Annual Meeting & Exposition, October 12–14 in Washington, D.C., and the ThinkEquity investor conference, October 15 in New York, NY.

AUSA 2026: October 12–14, Washington, D.C.

Mobilicom will showcase its robust portfolio of hardware, software and cybersecurity solutions in Hall DE, Booth #7305 at the Walter E. Washington Convention Center, including a new solution designed for secure, high-throughput communications addressing the growing data demands of next-generation autonomous missions.

“As autonomous defense operations evolve, missions are becoming more complex and increasingly data intensive. This shift makes the ability to move and protect mission-critical data reliably and at scale more critical than ever,” said Oren Elkayam, CEO and Founder of Mobilicom. “At AUSA, we will showcase how Mobilicom is addressing these evolving requirements. We look forward to engaging with defense leaders and industry partners at AUSA, followed by current and potential investors at ThinkEquity.”

The AUSA Annual Meeting & Exposition is a leading land power exposition and professional development forum in North America, convening participants from across the defense sector. With over 40,000 attendees, 750+ exhibits, and representation from 100+ countries, this three-day event is where the global defense community converges to shape the future of national security.

For more information about AUSA 2026, visit the event website.

ThinkEquity Conference: October 15, New York, NY

Mobilicom will present as part of the Drone Track at the ThinkEquity investor conference on Thursday, October 15, 2026, at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel in New York City. The presentation will highlight Mobilicom’s business and growth opportunities across the global drone, robotics and defense markets. Management will also hold one-on-one meetings with investors at the conference.

Investors interested in connecting with Mobilicom may contact ir@mobilicom.com or their ThinkEquity representative. Additional conference information is available on the ThinkEquity website.

About Mobilicom

Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom’s large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world’s largest drone manufacturers, Mobilicom’s end-to-end solutions are used in mission-critical functions.

For investors, please use https://ir.mobilicom.com/  
For company, please use www.mobilicom.com

Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Mobilicom Limited’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission.

Forward-looking statements contained in this announcement are made as of this date, and Mobilicom Limited undertakes no duty to update such information except as required under applicable law.

For more information on Mobilicom, please contact:

Chris Donovan
Mobilicom Ltd
ir@mobilicom.com

Expanded Portfolio Addresses Demand for Secure, High-Throughput Communications Across Swarm-Scale Unmanned Operations

Palo Alto, California, Oct. 07, 2026 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB) (“Mobilicom” or the “Company”), a provider of cybersecure solutions for drones and robotics today announced its participation in the Association of the United States Army’s (AUSA) 2026 Annual Meeting & Exposition, October 12–14 in Washington, D.C., and the ThinkEquity investor conference, October 15 in New York, NY.

AUSA 2026: October 12–14, Washington, D.C.

Mobilicom will showcase its robust portfolio of hardware, software and cybersecurity solutions in Hall DE, Booth #7305 at the Walter E. Washington Convention Center, including a new solution designed for secure, high-throughput communications addressing the growing data demands of next-generation autonomous missions.

“As autonomous defense operations evolve, missions are becoming more complex and increasingly data intensive. This shift makes the ability to move and protect mission-critical data reliably and at scale more critical than ever,” said Oren Elkayam, CEO and Founder of Mobilicom. “At AUSA, we will showcase how Mobilicom is addressing these evolving requirements. We look forward to engaging with defense leaders and industry partners at AUSA, followed by current and potential investors at ThinkEquity.”

The AUSA Annual Meeting & Exposition is a leading land power exposition and professional development forum in North America, convening participants from across the defense sector. With over 40,000 attendees, 750+ exhibits, and representation from 100+ countries, this three-day event is where the global defense community converges to shape the future of national security.

For more information about AUSA 2026, visit the event website.

ThinkEquity Conference: October 15, New York, NY

Mobilicom will present as part of the Drone Track at the ThinkEquity investor conference on Thursday, October 15, 2026, at 1:30 p.m. Eastern Time at the Mandarin Oriental Hotel in New York City. The presentation will highlight Mobilicom’s business and growth opportunities across the global drone, robotics and defense markets. Management will also hold one-on-one meetings with investors at the conference.

Investors interested in connecting with Mobilicom may contact ir@mobilicom.com or their ThinkEquity representative. Additional conference information is available on the ThinkEquity website.

About Mobilicom

Mobilicom is a leading provider of cybersecure robust solutions for the rapidly growing defense and commercial drones and robotics market. Mobilicom’s large portfolio of field-proven technologies includes cybersecurity, software, hardware, and professional services that power, connect, guide, and secure drones and robotics. Through deployments across the globe with over 50 customers, including the world’s largest drone manufacturers, Mobilicom’s end-to-end solutions are used in mission-critical functions.

For investors, please use https://ir.mobilicom.com/  
For company, please use www.mobilicom.com

Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Mobilicom Limited’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission.

Forward-looking statements contained in this announcement are made as of this date, and Mobilicom Limited undertakes no duty to update such information except as required under applicable law.

For more information on Mobilicom, please contact:

Chris Donovan
Mobilicom Ltd
ir@mobilicom.com

Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs

Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform (“GCP”).

The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment is expected to enable MitoCareX to align computing capacity with program needs, while supporting controlled access to shared scientific data and efficient internal workflows as its research needs evolve.

Building on these capabilities, MitoCareX’s GCP-based environment is expected to centralize the management of scientific data, apply a consistent framework for user permissions across its scientific and technical activities, and enable computing and storage resources to adapt to changing project requirements. The environment is being designed to support data integrity, strengthen access governance and promote operational continuity throughout MitoCareX’s research activities.

“Transitioning MitoCareX’s computational platform to a GCP-based environment represents an important step in strengthening the operating foundation for the next phase of MitoCareX’s development,” said David Palach, Chief Executive Officer of Nexentis Technologies Inc. “This deployment is intended to provide MitoCareX’s scientific teams with an adaptable environment aligned with the changing needs of our discovery programs. We believe that combining operational flexibility with rigorous oversight of scientific data will support disciplined execution of our research strategy as these programs progress.”

Taken together, these capabilities are intended to provide MitoCareX with a resilient framework for managing its computational research. The framework is expected to support existing programs and enable the evaluation of additional discovery opportunities as research priorities change. Continued development of MitoCareX’s scientific and technical capabilities remains an important element of Nexentis’s strategy to advance focused drug discovery programs and support long-term value creation.

About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated benefits of deploying MitoCareX’s computational drug discovery infrastructure on Google Cloud Platform, the expected enhancement of computational capacity, data governance and operational flexibility, and the potential impact of these capabilities on MitoCareX’s research activities and drug discovery efforts. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs

Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform (“GCP”).

The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment is expected to enable MitoCareX to align computing capacity with program needs, while supporting controlled access to shared scientific data and efficient internal workflows as its research needs evolve.

Building on these capabilities, MitoCareX’s GCP-based environment is expected to centralize the management of scientific data, apply a consistent framework for user permissions across its scientific and technical activities, and enable computing and storage resources to adapt to changing project requirements. The environment is being designed to support data integrity, strengthen access governance and promote operational continuity throughout MitoCareX’s research activities.

“Transitioning MitoCareX’s computational platform to a GCP-based environment represents an important step in strengthening the operating foundation for the next phase of MitoCareX’s development,” said David Palach, Chief Executive Officer of Nexentis Technologies Inc. “This deployment is intended to provide MitoCareX’s scientific teams with an adaptable environment aligned with the changing needs of our discovery programs. We believe that combining operational flexibility with rigorous oversight of scientific data will support disciplined execution of our research strategy as these programs progress.”

Taken together, these capabilities are intended to provide MitoCareX with a resilient framework for managing its computational research. The framework is expected to support existing programs and enable the evaluation of additional discovery opportunities as research priorities change. Continued development of MitoCareX’s scientific and technical capabilities remains an important element of Nexentis’s strategy to advance focused drug discovery programs and support long-term value creation.

About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/

About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd, a drug discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

For additional details, please visit https://nexentistech.com/

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the anticipated benefits of deploying MitoCareX’s computational drug discovery infrastructure on Google Cloud Platform, the expected enhancement of computational capacity, data governance and operational flexibility, and the potential impact of these capabilities on MitoCareX’s research activities and drug discovery efforts. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

CINCINNATI, Oct. 07, 2026 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (“Hillman”), a leading provider of hardware and related products, plans to host a conference call to discuss its results for the thirteen and thirty-nine weeks ended September 26, 2026 on Tuesday, November 3, 2026 at 8:30 a.m. Eastern Time. Hillman plans to issue its earnings release after market close on Monday, November 2, 2026.

President and Chief Executive Officer Jon Michael Adinolfi and Chief Financial Officer Rocky Kraft will host the results presentation.

Results Presentation Details:

Date: Tuesday, November 3, 2026
Time: 8:30 a.m. Eastern Time
Listen-Only Webcast: https://edge.media-server.com/mmc/p/diivckgp

Sell-side analysts wishing to participate in the call’s live question and answer session must register by clicking here: https://register-conf.media-server.com/register/BI44e7392015d14526bf6b62062b15c6e3

A webcast replay will be available shortly after the conclusion of the presentation using the Listen-Only Webcast link above.

Hillman’s earnings release and quarterly results presentation are expected to be filed with the SEC and posted to its website, https://ir.hillmangroup.com, before the results presentation begins.

About Hillman Solutions Corp.
Founded in 1964 and headquartered in Cincinnati, Hillman is a leading provider of hardware and related products serving retail, pro distribution, and industrial customers. Over the last 60-plus years, Hillman has built a legacy of service and growth by forming strategic partnerships with North America’s leading home improvement, hardware, and farm and fleet retailers. Hillman differentiates itself from the competition with its dedicated field sales team of 1,200+ associates, direct-to-store distribution capabilities, and world class global sourcing and supply chain expertise. The company offers an extensive product portfolio of over 150,000 SKUs, including fasteners (power screws, nuts, and bolts), hardware (builder’s hardware, door locks, rope & chain, accessories), project gear & supplies (gloves, work gear, paint & cleaning sundries), and key and engraving services (key duplication, auto keys, and engraving). Hillman is committed to delivering exceptional customer service, innovative products, and dependable solutions to its customers and regularly earns vendor of the year recognition from top customers. For more information on Hillman, visit www.hillman.com.

Investor Contact
Michael Koehler
Vice President – Corporate Development, Investor Relations, Treasury
513-826-5495
IR@hillmangroup.com

Source: Hillman Solutions Corp.

CINCINNATI, Oct. 07, 2026 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (“Hillman”), a leading provider of hardware and related products, plans to host a conference call to discuss its results for the thirteen and thirty-nine weeks ended September 26, 2026 on Tuesday, November 3, 2026 at 8:30 a.m. Eastern Time. Hillman plans to issue its earnings release after market close on Monday, November 2, 2026.

President and Chief Executive Officer Jon Michael Adinolfi and Chief Financial Officer Rocky Kraft will host the results presentation.

Results Presentation Details:

Date: Tuesday, November 3, 2026
Time: 8:30 a.m. Eastern Time
Listen-Only Webcast: https://edge.media-server.com/mmc/p/diivckgp

Sell-side analysts wishing to participate in the call’s live question and answer session must register by clicking here: https://register-conf.media-server.com/register/BI44e7392015d14526bf6b62062b15c6e3

A webcast replay will be available shortly after the conclusion of the presentation using the Listen-Only Webcast link above.

Hillman’s earnings release and quarterly results presentation are expected to be filed with the SEC and posted to its website, https://ir.hillmangroup.com, before the results presentation begins.

About Hillman Solutions Corp.
Founded in 1964 and headquartered in Cincinnati, Hillman is a leading provider of hardware and related products serving retail, pro distribution, and industrial customers. Over the last 60-plus years, Hillman has built a legacy of service and growth by forming strategic partnerships with North America’s leading home improvement, hardware, and farm and fleet retailers. Hillman differentiates itself from the competition with its dedicated field sales team of 1,200+ associates, direct-to-store distribution capabilities, and world class global sourcing and supply chain expertise. The company offers an extensive product portfolio of over 150,000 SKUs, including fasteners (power screws, nuts, and bolts), hardware (builder’s hardware, door locks, rope & chain, accessories), project gear & supplies (gloves, work gear, paint & cleaning sundries), and key and engraving services (key duplication, auto keys, and engraving). Hillman is committed to delivering exceptional customer service, innovative products, and dependable solutions to its customers and regularly earns vendor of the year recognition from top customers. For more information on Hillman, visit www.hillman.com.

Investor Contact
Michael Koehler
Vice President – Corporate Development, Investor Relations, Treasury
513-826-5495
IR@hillmangroup.com

Source: Hillman Solutions Corp.

Approximately C$4.5 million initial tranche delivered under previously announced contract valued at up to C$9 million; customer begins exercising second-tranche option

MIRABEL, Québec, Oct. 07, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-headquartered global aerospace and defence company, today announced that it has completed delivery of the uncrewed aircraft fleet under the initial approximately C$4.5 million tranche of its previously announced ISR training system contract with a NATO partner.

The contract, announced on December 15, 2025, has a potential aggregate value of up to C$9 million. The customer has begun exercising its option under the second tranche, with Volatus receiving additional orders under the previously announced contract. The unexercised balance remains available at the customer’s option through the end of 2027.

The fleet addresses an immediate training requirement by enabling defence personnel to develop foundational skills in drone flight, navigation and basic intelligence, surveillance and reconnaissance (ISR). The systems are designed for repeated use by new operators in controlled training environments, allowing personnel to build confidence and practical experience before progressing to more advanced operational platforms.

“This delivery represents an important milestone in the continued growth of our defence business,” said Glen Lynch, CEO of Volatus. “It demonstrates our ability to respond to clearly defined allied requirements with practical, scalable uncrewed solutions. Just as importantly, it strengthens our relationships with NATO allies and positions Volatus to support the growing demand for uncrewed systems, training and sustainment worldwide. The additional orders demonstrate continued customer commitment to the program and reinforce our ability to bring together aircraft, integration, training and support to meet allied requirements.”

This delivery completes the initial fleet shipment following the supply-chain disruptions previously disclosed in the Company’s quarterly reporting.

The program includes a fleet of durable, commercially derived training aircraft, integrated control interfaces, technical and operational documentation, instructor familiarization, warranty coverage and lifecycle support. The systems feature intuitive controls and automated safety functions suited to personnel with limited prior UAS experience.

Specific system configurations remain confidential under the terms of the agreement.

As NATO members increase their adoption of uncrewed technologies, the ability to develop trained operators is becoming an essential component of defence readiness. Volatus’ combination of aircraft, integration, training and sustainment capabilities enables the Company to address immediate customer requirements while supporting the longer-term development of uncrewed aviation capacity.

“Training is foundational to the effective adoption of uncrewed systems,” added Lynch. “This program gives new operators the tools and experience they need to begin building that capability, while creating a pathway toward more advanced systems and applications.”

The delivery adds to Volatus’ growing defence portfolio and provides a foundation for potential follow-on orders and broader opportunities across allied markets.

About Volatus Aerospace

Volatus Aerospace is a Canadian-headquartered global aerospace and defence company delivering intelligence and cargo solutions through piloted and remotely piloted aircraft systems. With operations, training programs and strategic partnerships spanning multiple continents, Volatus supports government, defence and commercial customers worldwide. The Company leverages advanced technologies, remote operations expertise and aviation experience to solve complex operational challenges in demanding environments.

Forward-Looking Information

This news release contains statements that constitute “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities, events, developments and operating performance. Often, but not always, forward-looking information and forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “seeks”, “strategy” or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information includes information regarding: (i) the business plans, business outlook and expectations of the Company; and (ii) expectations for other economic, business, and/or competitive factors.

Forward-looking information is based on currently available competitive, financial, and economic data and operating plans, strategies, or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement. 

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information and forward-looking statements reflect the Company’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include but are not limited to: the commercialization of drone flights beyond visual line of sight and potential benefits to the Company; and meeting the continued listing requirements of the TSX. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. The forward-looking information contained herein is made as of the date of this news release and, other than as required by law, the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

For additional information, please contact:

Volatus Aerospace Inc. 
Rob Walker, Chief Commercial Officer 
+1-833-865-2887 
investorrelations@volatusaerospace.com 
https://volatusaerospace.com 

Approximately C$4.5 million initial tranche delivered under previously announced contract valued at up to C$9 million; customer begins exercising second-tranche option

MIRABEL, Québec, Oct. 07, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-headquartered global aerospace and defence company, today announced that it has completed delivery of the uncrewed aircraft fleet under the initial approximately C$4.5 million tranche of its previously announced ISR training system contract with a NATO partner.

The contract, announced on December 15, 2025, has a potential aggregate value of up to C$9 million. The customer has begun exercising its option under the second tranche, with Volatus receiving additional orders under the previously announced contract. The unexercised balance remains available at the customer’s option through the end of 2027.

The fleet addresses an immediate training requirement by enabling defence personnel to develop foundational skills in drone flight, navigation and basic intelligence, surveillance and reconnaissance (ISR). The systems are designed for repeated use by new operators in controlled training environments, allowing personnel to build confidence and practical experience before progressing to more advanced operational platforms.

“This delivery represents an important milestone in the continued growth of our defence business,” said Glen Lynch, CEO of Volatus. “It demonstrates our ability to respond to clearly defined allied requirements with practical, scalable uncrewed solutions. Just as importantly, it strengthens our relationships with NATO allies and positions Volatus to support the growing demand for uncrewed systems, training and sustainment worldwide. The additional orders demonstrate continued customer commitment to the program and reinforce our ability to bring together aircraft, integration, training and support to meet allied requirements.”

This delivery completes the initial fleet shipment following the supply-chain disruptions previously disclosed in the Company’s quarterly reporting.

The program includes a fleet of durable, commercially derived training aircraft, integrated control interfaces, technical and operational documentation, instructor familiarization, warranty coverage and lifecycle support. The systems feature intuitive controls and automated safety functions suited to personnel with limited prior UAS experience.

Specific system configurations remain confidential under the terms of the agreement.

As NATO members increase their adoption of uncrewed technologies, the ability to develop trained operators is becoming an essential component of defence readiness. Volatus’ combination of aircraft, integration, training and sustainment capabilities enables the Company to address immediate customer requirements while supporting the longer-term development of uncrewed aviation capacity.

“Training is foundational to the effective adoption of uncrewed systems,” added Lynch. “This program gives new operators the tools and experience they need to begin building that capability, while creating a pathway toward more advanced systems and applications.”

The delivery adds to Volatus’ growing defence portfolio and provides a foundation for potential follow-on orders and broader opportunities across allied markets.

About Volatus Aerospace

Volatus Aerospace is a Canadian-headquartered global aerospace and defence company delivering intelligence and cargo solutions through piloted and remotely piloted aircraft systems. With operations, training programs and strategic partnerships spanning multiple continents, Volatus supports government, defence and commercial customers worldwide. The Company leverages advanced technologies, remote operations expertise and aviation experience to solve complex operational challenges in demanding environments.

Forward-Looking Information

This news release contains statements that constitute “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities, events, developments and operating performance. Often, but not always, forward-looking information and forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “seeks”, “strategy” or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information includes information regarding: (i) the business plans, business outlook and expectations of the Company; and (ii) expectations for other economic, business, and/or competitive factors.

Forward-looking information is based on currently available competitive, financial, and economic data and operating plans, strategies, or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement. 

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information and forward-looking statements reflect the Company’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include but are not limited to: the commercialization of drone flights beyond visual line of sight and potential benefits to the Company; and meeting the continued listing requirements of the TSX. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. The forward-looking information contained herein is made as of the date of this news release and, other than as required by law, the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

For additional information, please contact:

Volatus Aerospace Inc. 
Rob Walker, Chief Commercial Officer 
+1-833-865-2887 
investorrelations@volatusaerospace.com 
https://volatusaerospace.com